![](https://www.m-ventures.com/media/pages/portfolio/padlock-therapeutics/33eaf50547-1695045646/padlock.png)
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Padlock Therapeutics, Inc. (“Padlock”) announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.